☆ 4.7 Article

Tumor Treating Fields (TTFields) Concomitant with Immune Checkpoint Inhibitors Are Therapeutically Effective in Non-Small Cell Lung Cancer (NSCLC) In Vivo Model

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Oncology

Tumor-associated macrophages in cancer: recent advancements in cancer nanoimmunotherapies

Nisha Kumari et al.

Summary: Cancer immunotherapy has had limited success, but nanoparticles have emerged as crucial tools in targeting tumor-associated macrophages (TAMs) and improving therapy outcomes. Current strategies include restricting TAMs survival, inhibiting TAMs recruitment, and repolarizing tumor-supportive TAMs to an antitumor phenotype.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2022)

添加到收藏夹

Article Oncology

Checkpoint: Inspecting the barriers in glioblastoma immunotherapies

Isabelle Preddy et al.

SEMINARS IN CANCER BIOLOGY (2022)

添加到收藏夹

Article Oncology

IFN-Gamma Expression in the Tumor Microenvironment and CD8-Positive Tumor-Infiltrating Lymphocytes as Prognostic Markers in Urothelial Cancer Patients Receiving Pembrolizumab

Toru Sakatani et al.

Summary: The study investigated the expression of immune markers in the tumor microenvironment of 26 advanced urothelial carcinoma patients receiving Pembrolizumab treatment. High levels of CD8(+) tumor-infiltrating lymphocytes were associated with favorable objective responses, progression-free survival, and overall survival. Additionally, high interferon-gamma (IFN gamma) expression levels were linked to longer post-progression survival. Low infiltration of CD8(+) TILs and low IFN gamma expression were identified as an independent prognostic factor for an unfavorable response to Pembrolizumab.

CANCERS (2022)

添加到收藏夹

Article Oncology

Hallmarks of Resistance to Immune-Checkpoint Inhibitors

Maria Karasarides et al.

Summary: This study systematically explores key nodes of immune resistance through the lens of known biological processes, providing support and guidance for future immune resistance research. Integration of multiomic high-dimensional analyses with patient data can help guide effective drug development strategies and improve patient outcomes.

CANCER IMMUNOLOGY RESEARCH (2022)

添加到收藏夹

Review Oncology

The Mechanisms of Action of Tumor Treating Fields

Justin C. Moser et al.

Summary: TTFields, a new modality of cancer treatment, achieve their anticancer effects through multiple mechanisms of action and have the ability to be useful for many cancer types in combination with different treatment modalities.

CANCER RESEARCH (2022)

添加到收藏夹

Article Biology

Current status of the preclinical evaluation of alternating electric fields as a form of cancer therapy

Christoph Pohling et al.

BIOELECTROCHEMISTRY (2022)

添加到收藏夹

Article Medicine, Research & Experimental

Tumor Treating Fields dually activate STING and AIM2 inflammasomes to induce adjuvant immunity in glioblastoma

Dongjiang Chen et al.

Summary: TTFields, a novel therapy for GBM and other solid tumors, disrupts mitotic spindle and induces inflammation to exert its anti-tumor effects. The study reveals that TTFields can activate DNA sensors and inflammasomes to produce immune response, leading to antitumor immunity and cure.

JOURNAL OF CLINICAL INVESTIGATION (2022)

添加到收藏夹

Article Oncology

Non-Small-Cell Lung Cancer in 2022: A Review for General Practitioners in Oncology

Hamid Mithoowani et al.

Summary: This article presents a comprehensive review of the current best practices in the treatment of non-small cell lung cancer in Canada, covering screening, management of early stage and locally-advanced disease, as well as management of patients with metastatic disease. It also focuses on the incorporation of immunotherapy into practice and its associated toxicities.

CURRENT ONCOLOGY (2022)

添加到收藏夹

Review Oncology

A review of glioblastoma immunotherapy

Ravi Medikonda et al.

Summary: Current immunotherapy treatments for glioblastoma, including checkpoint inhibitors and vaccine therapy, have shown disappointing results in clinical trials due to the highly immunosuppressive environment and therapy resistance mechanisms of the tumor. Ongoing research is focusing on exploring combination therapies and novel treatment strategies beyond immune checkpoint therapies, as well as establishing synergy between immunotherapy and current standard of care to improve treatment outcomes. Recent advances in personalized neoantigen vaccines suggest a shift towards personalized, patient-specific treatment for glioblastoma.

JOURNAL OF NEURO-ONCOLOGY (2021)

添加到收藏夹

Review Medicine, Research & Experimental

Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance

Sreya Bagchi et al.

Summary: This article highlights the significance of immune checkpoint inhibitors in cancer immunotherapy and the research findings on the changes in local and systemic immune cells after treatment. It emphasizes the need for understanding the requirements for an effective and safe antitumor immune response following ICI therapy.

ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 16, 2021 (2021)

添加到收藏夹

Article Genetics & Heredity

Roles of HMGBs in Prognosis and Immunotherapy: A Pan-Cancer Analysis

Tong Lin et al.

Summary: This study revealed that HMGBs could serve as promising predictive biomarkers for cancer prognosis and immunotherapeutic response, and also as immunotherapy targets for multiple cancers.

FRONTIERS IN GENETICS (2021)

添加到收藏夹

Review Oncology

Landscape of Myeloid-derived Suppressor Cell in Tumor Immunotherapy

Zhaonian Hao et al.

Summary: MDSC play vital roles in cancer microenvironment, influencing the responses to immunotherapies and prognosis of cancer patients. Therefore, proposing MDSC-inhibiting strategies becomes crucial in the field of cancer immunotherapies.

BIOMARKER RESEARCH (2021)

添加到收藏夹

Article Immunology

T Cells Retain Pivotal Antitumoral Functions under Tumor-Treating Electric Fields

Gil Diamant et al.

Summary: TTFields reduce the viability of proliferating T cells but have little effect on nonproliferating T cells. T cells cultured under TTFields retain functionality, exhibiting similar IFN-gamma secretion, cytotoxic degranulation, and PD1 upregulation. Glioblastoma Ag-specific T cells and CAR-T cells also maintain viability and functionality under TTFields. The treatment leads to a shift in immune signature from protumoral to antitumoral, suggesting potential for combination with immunotherapy in clinical trials.

JOURNAL OF IMMUNOLOGY (2021)

添加到收藏夹

Review Oncology

Current Landscape of Non-Small Cell Lung Cancer: Epidemiology, Histological Classification, Targeted Therapies, and Immunotherapy

Olga Rodak et al.

Summary: Non-small cell lung cancer (NSCLC) is a common type of cancer worldwide, with its incidence influenced by various factors. With an increasing understanding of NSCLC biology, new treatment strategies such as targeted therapy and immunotherapy continue to emerge. However, successful treatment for certain molecular sub-types remains a challenge.

CANCERS (2021)

添加到收藏夹

Article Oncology

Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy

Tali Voloshin et al.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)

添加到收藏夹

Article Oncology

Tumor Treating Fields (TTFields) Hinder Cancer Cell Motility through Regulation of Microtubule and Actin Dynamics

Tali Voloshin et al.

CANCERS (2020)

添加到收藏夹

Review Immunology

A guide to cancer immunotherapy: from T cell basic science to clinical practice

Alex D. Waldman et al.

NATURE REVIEWS IMMUNOLOGY (2020)

添加到收藏夹

Article Oncology

Cancer-cell-secreted CXCL11 promoted CD8+ T cells infiltration through docetaxel-induced-release of HMGB1 in NSCLC

Qun Gao et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)

添加到收藏夹

Review Oncology

Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications

Yuxin Lin et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)

添加到收藏夹

Article Biochemistry & Molecular Biology

eIF2α phosphorylation is pathognomonic for immunogenic cell death

Lucillia Bezu et al.

CELL DEATH AND DIFFERENTIATION (2018)

添加到收藏夹

Article Medicine, Research & Experimental

Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression

Heng Lin et al.

JOURNAL OF CLINICAL INVESTIGATION (2018)

添加到收藏夹

Article Oncology

eIF2α phosphorylation: A hallmark of immunogenic cell death

Lucillia Bezu et al.

ONCOIMMUNOLOGY (2018)

添加到收藏夹

Review Oncology

Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, efficacy, and Limitations

Judith A. Seidel et al.

FRONTIERS IN ONCOLOGY (2018)

添加到收藏夹

Review Oncology

Tumor-Treating Fields: A Fourth Modality in Cancer Treatment

Elijah J. Mun et al.

CLINICAL CANCER RESEARCH (2018)

添加到收藏夹

Article Biochemistry & Molecular Biology

Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy

Antoni Ribas et al.

CELL (2017)

添加到收藏夹

Review Biochemistry & Molecular Biology

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy

Padmanee Sharma et al.

CELL (2017)

添加到收藏夹

Review Oncology

Immune-modulating properties of ionizing radiation: rationale for the treatment of cancer by combination radiotherapy and immune checkpoint inhibitors

Anja Derer et al.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)

添加到收藏夹

News Item Biotechnology & Applied Microbiology

Biomarker search illuminates cancer immune biology

Katie Kingwell

NATURE REVIEWS DRUG DISCOVERY (2016)

添加到收藏夹

Review Oncology

HMGB1 overexpression as a prognostic factor for survival in cancer: a meta-analysis and systematic review

Tengyun Wu et al.

ONCOTARGET (2016)

添加到收藏夹

Article Oncology

Interferon-γ Production by Peripheral Lymphocytes Predicts Survival of Tumor-Bearing Mice Receiving Dual PD-1/CTLA-4 Blockade

Michael J. McNamara et al.

CANCER IMMUNOLOGY RESEARCH (2016)

添加到收藏夹

Article Oncology

Prognostic value of HMGB1 in early breast cancer patients under neoadjuvant chemotherapy

Ruth Exner et al.

CANCER MEDICINE (2016)

添加到收藏夹

Review Biotechnology & Applied Microbiology

Combination cancer immunotherapy and new immunomodulatory targets

Kathleen M. Mahoney et al.

NATURE REVIEWS DRUG DISCOVERY (2015)

添加到收藏夹

Review Multidisciplinary Sciences

Neoantigens in cancer immunotherapy

Ton N. Schumacher et al.

SCIENCE (2015)

添加到收藏夹

Review Oncology

eIF2α phosphorylation as a biomarker of immunogenic cell death

Oliver Kepp et al.

SEMINARS IN CANCER BIOLOGY (2015)

添加到收藏夹

Review Oncology

Adaptive Immune Resistance: How Cancer Protects from Immune Attack

Antoni Ribas

CANCER DISCOVERY (2015)

添加到收藏夹

Review Oncology

Alternating Electric Fields (Tumor-Treating Fields Therapy) Can Improve Chemotherapy Treatment Efficacy in Non-Small Cell Lung Cancer Both In Vitro and In Vivo

Moshe Giladi et al.

SEMINARS IN ONCOLOGY (2014)

添加到收藏夹

Review Immunology

Immunogenic Cell Death in Cancer Therapy

Guido Kroemer et al.

ANNUAL REVIEW OF IMMUNOLOGY, VOL 31 (2013)

添加到收藏夹

Article Oncology

Immunogenicity of Murine Solid Tumor Models as a Defining Feature of In Vivo Behavior and Response to Immunotherapy

Melissa G. Lechner et al.

JOURNAL OF IMMUNOTHERAPY (2013)

添加到收藏夹

Review Cell Biology

At the Bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy

Andrew M. Intlekofer et al.

JOURNAL OF LEUKOCYTE BIOLOGY (2013)

添加到收藏夹

Article Oncology

Hypericin-based photodynamic therapy induces surface exposure of damage-associated molecular patterns like HSP70 and calreticulin

Abhishek D. Garg et al.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)

添加到收藏夹

Review Oncology

Immunogenic cell death and DAMPs in cancer therapy

Dmitri V. Krysko et al.

NATURE REVIEWS CANCER (2012)

添加到收藏夹

Article Oncology

Alternating electric fields (TTFields) inhibit metastatic spread of solid tumors to the lungs

Eilon D. Kirson et al.

CLINICAL & EXPERIMENTAL METASTASIS (2009)

添加到收藏夹

Article Immunology

Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein

Hirotaka Kazama et al.

IMMUNITY (2008)

添加到收藏夹

Review Immunology

The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy

Lionel Apetoh et al.

IMMUNOLOGICAL REVIEWS (2007)

添加到收藏夹

Article Biochemistry & Molecular Biology

Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

Lionel Apetoh et al.

NATURE MEDICINE (2007)

添加到收藏夹

Article Biochemistry & Molecular Biology

Calreticulin exposure dictates the immunogenicity of cancer cell death

Michel Obeid et al.

NATURE MEDICINE (2007)

添加到收藏夹

Article Immunology

Lineage relationship and protective immunity of memory CD8 T cell subsets

EJ Wherry et al.

NATURE IMMUNOLOGY (2003)

添加到收藏夹

Article Multidisciplinary Sciences

Release of chromatin protein HMGB1 by necrotic cells triggers inflammation

P Scaffidi et al.

NATURE (2002)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.